[Presentation] How the COVID-19 Pandemic Impacted Clinical Development from an Operations Perspective
Medpace’s Director of Clinical Trial Management, Alex Krutilin, took the virtual stage at the Outsourcing in Clinical Trials UK & Ireland conference to discuss how…
A New Paradigm in Infectious Diseases Treatment & Prophylaxis Shaped by the Current Pandemic
The COVID-19 pandemic will end, or as any pandemic in the past, will lose its momentum. Yet, the precedents and the new paradigms formed in…
Medpace Clinical Pharmacology Unit working with HiFiBIO Therapeutics on a SARS-CoV-2 ID-neutralizing antibody for the treatment and prevention of COV19
In a recent news release, HiFiBiO Therapeutics announced the successful completion of the first cohort of the Phase I study (NCT04590430) of HFB30132 which was…
Working at Medpace During COVID-19
While COVID-19 has had many effects on how we run our clinical trials as we continue to provide essential services during the pandemic, we’ve also…
COVID-19 Webinars – Medpace Assembles Team of Experts to Discuss Considerations for Future SARS-CoV-2 Development
In these upcoming webinars, experts from Medpace’s medical department, regulatory, and operational teams will provide insights and considerations on how to accelerate product development for…
Minimizing Disruption to Clinical Trials During COVID-19
Medpace is committed to keeping Sponsors on PACE to maintain regular activity during this irregular time.
COVID-19 Laboratory Testing: Medpace Central Labs
To serve our Sponsors in their COVID-19 programs, Medpace has expedited COVID-19 assay validations to meet clinical trial testing standards.